TD Cowen Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
Stifel Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $295
Goldman Sachs Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $50
Buy Rating Affirmed for BridgeBio Pharma Amidst ATTR-CM Treatment Market Dynamics
Alnylam Pharmaceuticals Analyst Ratings
BofA Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $42
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $400
J.P. Morgan Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,025 to $1,113
Evercore Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $515
Eli Lilly & Co: Strategic Pricing and Market Expansion Fuel Buy Rating
BofA Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $42
Eli Lilly Analyst Ratings
B.Riley Financial Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $92
Buy Rating Affirmed for Cytokinetics Amid Strong Cardiac Myosin Inhibitor Prospects and Positive Market Response
BMO Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $300
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $43
Alnylam Pharmaceuticals Price Target Raised to $280.00/Share From $248.00 by JP Morgan
RBC Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $300
J.P. Morgan Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating